Are you passionate about improving diabetes treatment? Are you meticulous in your work? Are you an innovative, team player? If so, then you will want to contact us! Thermalin is looking for a Research Associate – Protein Formulation to join our team. In this role, you will formulate insulin analogs for preclinical development.
Research Associate Responsibilities:
Formulate novel insulin analogs using established protocols
Quantify insulin analogs using reverse-phase (RP) analytical chromatography
Characterize insulin formulations with novel excipients using various biochemical methods
Develop new formulation schemes for insulin analogs
Optimize procedures and protocols to improve throughput
Perform laboratory tasks safely, rapidly, and efficiently
Report results in written and verbal format
Record results accurately and meticulously
Successful Research Associate Candidates Will Have:
An MS in Biochemistry or related science in addition to appropriate laboratory experience.
A minimum of 1 year experience in an industry setting is required.
At least 3 distinct, observable examples where achieved meaningful excellence.
Excellent “hands” in executing laboratory methods, particularly handling proteins.
Experience using analytical H/UPLC, preferably reverse phase.
Successful Research Associate Candidates Will Be:
Data driven decision-maker.
Excellent project planner with strong time management abilities.
Good listener. Strong, concise, and consistent written and oral communication.
Meticulous and detail oriented, responsible & mature.
Passionate, committed to excellence; driven to make projects and company succeed.
Persistent/tenacious, proactive self-starter, thorough follow-up; problem solver.
Unafraid to initiate change and have a strong sense of urgency.
Collaborative; team player; sense of humor.
Comprehensive health insurance package
Incentive stock options and bonus plan eligibility
Thermalin is engineering new forms of insulin that will lower the burden of insulin use, increase patient adoption of and adherence to insulin therapy, improve patient lives and outcomes, and lower the cost of caring for people with Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).
Founded in 2010 based on pioneering work by Dr. Michael Weiss on the structure and function of insulin analogues, Thermalin is overcoming the limitations of existing insulin products by re-engineering the insulin molecule to be more stable and to act more selectively. Thermalin’s formulations of these new molecules enable new delivery devices and systems that will transform lives.
Work Authorization Employment is contingent upon a successful background check. Thermalin Inc. will only employ those who are legally authorized to work in the United States.